

ASX Announcement

12 December 2024

BCAL Diagnostics NATA Accreditation Clarification

BCAL Diagnostics Limited (ASX: BDX) ("BCAL" or "the Company") refers to its announcement earlier today that its development and clinical services laboratory in North Ryde, NSW, has received formal accreditation from the National Association of Testing Authorities Australia (NATA).

BCAL wishes to clarify and reconfirm that now that it has NATA accreditation for the laboratory, which is a major milestone for the Company, it is currently completing the necessary validation studies for BREASTEST®, which remains on track to be made available to clinicians in the first quarter of 2025.

This announcement has been approved by the Executive Chair for release to the ASX.

ENDS

For further information:

Jayne Shaw

Executive Chair

jshaw@bcaldiagnostics.com

Shane Ryan

Chief Executive Officer

sryan@bcaldiagnostics.com

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating excellent performance independent of breast tissue density. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>